on Marinomed Biotech AG
Marinomed Biotech AG Reveals Clinical Success of Carragelose Nasal Spray
Marinomed Biotech AG has announced the publication of clinical data for their Carragelose nasal spray in the International Journal of General Medicine. The study showcases the product's efficacy in relieving nasal congestion for patients with allergic rhinitis.
The nasal spray combines Carragelose, known for its protective effects, with Sorbitol, renowned for its decongestant properties. Clinical trials demonstrated significant improvement in breathing for patients when compared to a placebo. Importantly, this effect occurs without the habituation associated with common decongestant sprays.
The study involved a double-blind, cross-over trial where participants with grass pollen allergies saw increased nasal airflow post-treatment. This advancement supports the nasal spray's application for both allergy and cold-induced congestion.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Marinomed Biotech AG news